A Novel Risk-Scoring System to Identify the Potential Population Benefiting From Adjuvant Chemotherapy for Node-Negative TNBC Patients With Tumor Size Less Than 1 cm.

Li, Yijun; Ma, Rulan; Chen, Heyan; Pu, Shengyu; Xie, Peiling; He, Jianjun; Zhang, Huimin

Li, Yijun; Ma, Rulan; Chen, Heyan; Pu, Shengyu; Xie, Peiling; He, Jianjun; Zhang, Huimin.

Afiliação

Li Y; Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Ma R; Department of Surgical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Chen H; Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Pu S; Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Xie P; Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
He J; Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Zhang H; Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Front Oncol ; 12: 788883, 2022.

Article em En | MEDLINE | ID: mdl-35814418

Palavras-chave

SEER; TNBC; adjuvant chemotherapy; nomogram; survival

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google